Sanofi Scores FDA Approval For Flu-Shot Facility In US

by Vandana Singh, Benzinga Editor

June 17, 2021 2:00 PM | 27 seconds read |

The FDA has approved Sanofi SA's SNY newly completed plant in Swiftwater, Pennsylvania.
The license will allow Sanofi to begin production of its Fluzone High-Dose vaccine for the 2021-22 flu season.
With $425 million of investment, the opening of the new plant will require Sanofi to add up to 200 employees.
Fluzone High-Dose is a quadrivalent vaccine targeting four flu strains.
Price Action: SNY shares are down 0.43% at $53.19 during the market trading session on the last check Thursday.

Posted In: Biotech News Health Care FDA General Briefs

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.